

27 January 2026

**ONDINE BIOMEDICAL INC.**

("Ondine Biomedical", "Ondine" or the "Company")

**Expanding Steriwave Use Across Vancouver Island**

**Island Health's New Regional Powerhouse, Cowichan District Hospital, Adopts Steriwave to Lead Vancouver Island in Surgical Innovation**

Ondine Biomedical Inc. (AIM: OBI) today announced that Cowichan District Hospital, a facility within the Island Health Authority in British Columbia, is adopting Steriwave® nasal photodisinfection as a standard component of pre-surgical protocols for its orthopedic patients to protect them from the growing risk of multidrug resistance.

The adoption of this cutting-edge technology comes as Cowichan Hospital undergoes a massive transformation and prepares for the historic opening of its new CAD 1.4 billion, 607,000-square-foot campus-three times the size of its current facility. The expansion nearly doubles the number of operating rooms, from four to seven, signaling Cowichan's emergence as a premier destination for complex orthopedic surgeries and joint replacements.

By integrating Ondine Biomedical's Steriwave system, Cowichan Hospital is providing its orthopedic patients with a "gold standard" of infection prevention. Steriwave uses a non-invasive, five-minute light-activated process to eliminate pathogens in the nose-a primary reservoir for bacteria that cause surgical site infections (SSIs). Unlike traditional antibiotics, Steriwave is effective immediately and does not contribute to the "superbug" crisis. For a hospital rapidly scaling surgical capacity to meet the needs of a growing population, this innovation is a critical safeguard. Adopters of the technology, such as the Mid Yorkshire Teaching NHS Trust in the UK, have seen hip and knee SSIs plummet by as much as 71%.

**A Future-Forward Medical Hub**

**Carolyn Cross, CEO of Ondine Biomedical Inc., commented:**

*"Cowichan is migrating from community hospital to a regional leader in innovation and we are proud to be part of that evolution. As this facility triples in size to become one of the most significant medical centers in British Columbia, the clinical team is ensuring that patient safety keeps pace with that growth. We are honored to support the Cowichan Valley in helping to protect patients and families from the growing threat of drug-resistant infections with our rapid and painless photodisinfection procedure."*

The adoption of Steriwave at the new Quwutsun Hilitun-ewt-hw facility underscores the hospital's commitment to "future-proofing" healthcare in the region, as it expands its emergency department to over 36 treatment spaces, becomes B.C.'s first fully electric and "Salmon-Safe" certified hospital, and increases the number of surgical procedure rooms by 200% to help reduce wait times for Vancouver Island residents.

**About Cowichan Hospital & Island Health**

Cowichan Hospital, operated by Island Health, is the primary acute care facility for the Cowichan Valley. With the completion of its new regional campus in 2026/2027, it will stand as one of the most technologically advanced hospitals in Canada, serving as a critical hub for surgical excellence, emergency care, and Indigenous health services.

**About Steriwave®**

Steriwave is a painless, two-step photodisinfection process. A light-activated agent is applied to the nostrils and then activated by a safe red light, triggering an oxidative burst that destroys bacteria, viruses, and fungi in minutes. It is a proven, non-antibiotic solution to preventing infections before they start.

**Enquiries:**

**Ondine Biomedical Inc.**

Carolyn Cross, CEO

[www.ondinebio.com](http://www.ondinebio.com)

+1 604 669 0555

or via Vane Percy & Roberts

**Strand Hanson Limited (Nominated & Joint Financial Adviser)**

James Harris, Richard Johnson

+44 (0)20 7409 3494

**Peel Hunt LLP (Broker & Joint Financial Adviser)**

James Steel, Dr. Chris Golden

+44 (0)20 7418 8900

**Vane Percy & Roberts (Media Contact)**

Simon Vane Percy

+44 (0)77 1000 5910

**About Ondine Biomedical Inc.**

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ("photodisinfection") for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials.

nasal photodisinfection and nasal photodisinfection by the company is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFFFLLLFIRFIR